Mirataz

Mirtazapine, the active ingredient in Mirataz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a veterinary oral formulation for use in cats. It is employed to stimulate appetite in feline patients experiencing weight loss or reduced food intake. It is indicated for cats with conditions such as chronic kidney disease, hyperthyroidism, or any illness causing anorexia.

GNH USA supplies Mirataz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, veterinary clinics, specialty pharmacies, and research institutions worldwide, ensuring quality and regulatory compliance.

Mirtazapine acts on central adrenergic and serotonergic pathways to increase appetite in feline patients.

- Appetite stimulation in cats: increases food intake in cats with anorexia. - Weight loss management in cats: helps maintain body condition in cats with chronic disease. - Pre‑operative preparation in cats: improves nutritional status before surgery. - Renal disease‑associated cachexia: supports caloric intake in cats with chronic kidney disease. - Cancer‑associated anorexia: aids in maintaining nutrition in cats with neoplasia.

Mirtazapine may cause a range of adverse reactions in cats.

Common Side Effects: - Sedation: mild to moderate drowsiness after dosing. - Increased appetite: marked rise in food consumption. - Weight gain: gradual increase in body mass. - Gastrointestinal upset: occasional vomiting or soft stools. - Ataxia: transient incoordination in some cats.

Serious or Rare Side Effects: - Severe hypersensitivity: rash, facial swelling, or anaphylaxis. - Neutropenia: marked reduction in white blood cells. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Seizures: rare occurrence of convulsive activity. - Cardiac arrhythmias: abnormal heart rhythms in predisposed animals.

When using Mirataz, veterinarians should consider several safety measures.

- Monitor body weight: track changes regularly to avoid excessive gain. - Assess liver function: obtain baseline hepatic enzymes before treatment. - Use caution in cardiac disease: monitor heart rate and rhythm. - Avoid in cats with known hypersensitivity to mirtazapine. - Observe for behavioral changes: report excessive sedation or aggression. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CYP1A2 inhibitors: may increase mirtazapine plasma levels. - CYP2D6 inhibitors: can raise exposure and risk of toxicity. - Other serotonergic agents: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CNS depressants: additive sedation may occur. - Anticholinergic drugs: may worsen constipation. - Diuretics: monitor electrolytes and hydration status.